Table I.
Association of clinicopathological characteristics with UBR5 expression status in patients with LCC (n=171).
| UBR5 expression, n (%) | |||||
|---|---|---|---|---|---|
| Characteristics | Entire cohort, n (%) | IHC negative (n=85) | IHC positive (n=86) | χ2 | P-value |
| Age, years | 0.874 | 0.350 | |||
| <70 | 128 (74.8) | 60 (70.6) | 68 (79.1) | ||
| ≥70 | 43 (25.2) | 25 (29.4) | 18 (20.9) | ||
| Sex | 0.491 | 0.712 | |||
| Male | 131 (76.7) | 62 (72.9) | 69 (80.2) | ||
| Female | 40 (23.3) | 23 (27.1) | 17 (19.8) | ||
| T stagea | 7.754 | <0.001 | |||
| T1-T2 | 101 (59.1) | 64 (75.3) | 37 (43.0) | ||
| T3-T4 | 70 (40.9) | 21 (24.7) | 49 (57.0) | ||
| N stagea | 9.173 | <0.001 | |||
| N0-N1 | 151 (88.3) | 80 (94.1) | 71 (82.6) | ||
| N2-N3 | 20 (11.7) | 5 (5.9) | 15 (17.4) | ||
| M stagea | 4.229 | 0.037 | |||
| M0 | 152 (88.9) | 78 (91.8) | 74 (86.0) | ||
| M1 | 19 (11.1) | 7 (8.2) | 12 (14.0) | ||
| Radiotherapy | 0.917 | 0.203 | |||
| Yes | 43 (25.0) | 18 (21.2) | 25 (29.1) | ||
| No | 128 (75.0) | 67 (78.8) | 61 (70.9) | ||
a
TNM scoring system: Tumor size, lymph nodes affected, metastases. Bold print indicates statistical significance. UBR5, ubiquitin protein ligase E3 component n-recognin 5; LCC, laryngeal carcinoma; IHC, immunohistochemistry.